FDA panel review triggers suspension of Grail's stock trading

FDA panel review triggers suspension of Grail's stock trading

Business

The U. S. Food and Drug Administration’s advisory committee reviewed Grail Inc.

’s multi-cancer early-detection blood test and temporarily halted trading of the company’s shares on September 24, 2026. Earlier, on September 21, 2026, Grail’s shares jumped more than 30% after the company released briefing documents ahead of the FDA panel meeting, Investor's Business Daily reported.

Actors

Grail Inc. Food and Drug Administration

Locations

United States

Articles

September 24, 2026
3 total
FDA advisory panel reviews Grail's blood cancer screening test, shares suspended
FDA advisory panel reviews Grail's blood cancer screening test, shares suspended

Investor's Business Daily • 24 Sep 15:18

The U.S. Food and Drug Administration’s advisory committee examined Grail's multi-cancer early detection blood test, leading to a temporary halt in trading of the company’s stock.

Credibility 72% Manip. 9% Center
FDA advisory panel reviews Grail's blood cancer screening test, shares suspended
FDA advisory panel reviews Grail's blood cancer screening test, shares suspended

Investor's Business Daily • 24 Sep 15:12

The U.S. Food and Drug Administration’s advisory committee examined Grail's multi-cancer early detection blood test, leading to a temporary halt in trading of the company’s stock.

Credibility 72% Manip. 9% Center
FDA advisory panel reviews Grail's blood cancer screening test, shares suspended
FDA advisory panel reviews Grail's blood cancer screening test, shares suspended

Investor's Business Daily • 24 Sep 12:04

The U.S. Food and Drug Administration’s advisory committee examined Grail's multi-cancer early detection blood test, leading to a temporary halt in trading of the company’s stock.

Credibility 72% Manip. 9% Center
September 23, 2026
1 total
FDA advisory panel reviews Grail's blood cancer screening test, shares suspended
FDA advisory panel reviews Grail's blood cancer screening test, shares suspended

Investor's Business Daily • 23 Sep 22:44

The U.S. Food and Drug Administration’s advisory committee examined Grail's multi-cancer early detection blood test, leading to a temporary halt in trading of the company’s stock.

Credibility 72% Manip. 9% Center
September 22, 2026
1 total
Grail shares surge ahead of FDA meeting on cancer-detecting blood test
Grail shares surge ahead of FDA meeting on cancer-detecting blood test

Investor's Business Daily • 22 Sep 11:37

Grail's stock rose more than 30% after briefing documents were released before a Food and Drug Administration panel meeting on its blood test for early cancer detection.

Credibility 68% Manip. 35% Center
September 21, 2026
1 total
Grail shares surge ahead of FDA meeting on cancer-detecting blood test
Grail shares surge ahead of FDA meeting on cancer-detecting blood test

Investor's Business Daily • 21 Sep 20:14

Grail's stock rose more than 30% after briefing documents were released before a Food and Drug Administration panel meeting on its blood test for early cancer detection.

Credibility 68% Manip. 35% Center

Related events